IMAB is expected to report earnings to rise 16.27% to -12 cents per share on November 29
Q3'23
Est.
$-0.13
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
Q1'24
Est.
$-0.22
Q4'23
Beat
by $0.36
The last earnings report on November 14 showed earnings per share of -10 cents, missing the estimate of -7 cents. With 262.16K shares outstanding, the current market capitalization sits at 80.68M.
a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.